GLP1R and Parkinson disease: For instance, NLY01, a GLP1R agonist, prevents the microglia-derived shift of astrocytes towards a C3+ neurotoxic phenotype in mouse model of PD, thereby mitigating the damage of dopaminergic neurons in mice [80, 81].